A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
A phase 2 multi-center investigation of efficacy of ABI-009 (nab-sirolimus) in patients with
advanced malignant perivascular epithelioid cell tumor (PEComa).
Funding Source - FDA OOPD